PDF icon Download PDF
Open Access
CC BY 4.0 · The Arab Journal of Interventional Radiology 2025; 09(01): 001-005
DOI: 10.1055/s-0044-1791222
Review Article

Early and Midterm Outcomes of Percutaneous Arteriovenous Fistula Creation

Ahmed Kamel Abdel Aal
1   Department of Diagnostic and Interventional Imaging, University of Texas Health Science Center at Houston, Houston, Texas, United States
,
Juri Bassuner
1   Department of Diagnostic and Interventional Imaging, University of Texas Health Science Center at Houston, Houston, Texas, United States
,
Husameddin El Khudari
2   Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama, United States
,
Reema F. Alrasheed
1   Department of Diagnostic and Interventional Imaging, University of Texas Health Science Center at Houston, Houston, Texas, United States
,
Shahroz Aziz
1   Department of Diagnostic and Interventional Imaging, University of Texas Health Science Center at Houston, Houston, Texas, United States
,
Mohamed Shahin
1   Department of Diagnostic and Interventional Imaging, University of Texas Health Science Center at Houston, Houston, Texas, United States
,
Ammar Almehmi
3   Department of Internal Medicine and Radiology, University of Alabama at Birmingham, Birmingham, Alabama, United States
,
Bridget Kowalczyk
1   Department of Diagnostic and Interventional Imaging, University of Texas Health Science Center at Houston, Houston, Texas, United States
› Author Affiliations
› Further Information
Also available ateRefMedOne
  Permissions and Reprints
Preview

Abstract

Surgical creation of arteriovenous fistulas has been the gold standard for vascular access in hemodialysis patients. However, recent advancements in endovascular technology, the need for alternative hemodialysis access options in nonsurgical candidates, and patient preference for nonsurgical approaches have led to the development of percutaneous arteriovenous fistula creation. Currently, there are two Food and Drug Administration (FDA) approved systems, namely WavelinQ and Ellipsys. The aim of this article is to review the available literature on the outcomes of percutaneous arteriovenous fistula creation. Studies have reported high technical success rates for both the WavelinQ and Ellipsys systems. However, re-interventions were necessary for maturation, maintenance of patency, and treatment of complications. Reported re-intervention rates have varied across studies, device used, and patient populations, ranging from 0.46 to 2.7 per patient-year. While percutaneous arteriovenous fistula creation shows promise in terms of technical success rates, patency, and patient satisfaction, the rate of re-interventions adds to the overall procedural burden and may impact cost-effectiveness.

Keywords

arteriovenous fistula - hemodialysis - WavelinQ - Ellipsys - re-interventions - patency - maturation


Publication History

Article published online:
07 November 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India